CClinicalTrials.gg
Status unknownNCT05551338Updated Sep 22, 2022

Serious Games for Parkinson's Disease

An interventional study of Serious games in Parkinson Disease and Parkinson, sponsored by Rutgers, The State University of New Jersey. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-22.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

IMPORTANCE: Rehabilitation games have been shown to improve cognitive function among people with various disorders but they have not been explored in home settings for patients with Parkinson's disease.

OBJECTIVE: To collect pilot data regarding the therapeutic benefits of self-administered rehabilitation games among patients with Parkinson's disease.

METHODS: The investigators will recruit 20 patients with Parkinson's disease into a pilot randomized controlled trial. Patients will be asked to perform two 30-minute sessions per week of training using serious games over a 3-month period in addition to conventional care or undergo only usual care. Patients will be evaluated at baseline, after 12 weeks of treatment, and at 24 weeks. Improvements in cognitive function, depression, quality of life, and mobility will be assessed.

RELEVANCE: Identifying whether self-administered rehabilitation games can lead to clinical improvements could have significant implications for the management of the disease.

02

Conditions studied

  • Parkinson Disease
  • Parkinson

Browse trials for

03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 20 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Rutgers, The State University of New Jersey is the lead sponsor of 496 studies on the registry; 130 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 30 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosis of mild to moderate PD (Hoehn \& Yahr 1-3)
  2. baseline MoCA score \<26
  3. ≥ 18 years-old
  4. ability to communicate and read in English
  5. have self-reported technological literacy (ie answer yes to the question asking if they are comfortable using technological devices)

Exclusion criteria

Exclusion Criteria:

  1. comorbid conditions that could affect the performance of the tasks (e.g. severe uncorrected vision impairment)
  2. severe cognitive impairment that would prevent the patient from understanding the tasks (MoCA\<16)
  3. if the subject does not want to be video recorded during the assessments or interview sessions
  4. if the subject does not have access to WiFi
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients will be asked to perform two 30-minute sessions per week of training using serious games over a 3-month period in their home setting in addition to their conventional care

    Other: Serious games

  • No intervention
    Control

    Patients will undergo only their conventional care

Interventions

  • OtherSerious games

    The training protocol will entail using a tablet-based program that includes 6 serious games. Patients will be asked to use the program twice a week for 3 months. The serious games that will be used in this study were developed to challenge short-term memory and selective attention in six different games. Each of the six games comprise 20 different stages of varying difficulty, where stage 1 is the easiest and stage 20 is the most difficult.

06

What researchers measure

Primary outcomes

  1. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills. The minimum score is 0 the maximum score is 30. Higher scores indicate higher cognitive function and lower scores indicate lower cognitive function.

    Time frame: Baseline (week 0)

  2. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills. The minimum score is 0 the maximum score is 30. Higher scores indicate higher cognitive function and lower scores indicate lower cognitive function.

    Time frame: Post-intervention (week 12)

  3. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills. The minimum score is 0 the maximum score is 30. Higher scores indicate higher cognitive function and lower scores indicate lower cognitive function.

    Time frame: Follow-up (week 24)

Secondary outcomes

  1. Digit span forward and backward

    These tests are used to measure working memory's number storage capacity.

    Time frame: Baseline (week 0), Post-intervention (week 12), Follow-up (week 24)

  2. Semantic fluency test

    This verbal fluency test has been shown to be effective in measuring executive functioning and language ability because the semantic/category subtest seems to require a higher level of thought processes since people have to think of meaning.

    Time frame: Baseline (week 0), Post-intervention (week 12), Follow-up (week 24)

  3. Geriatric depression scale

    The geriatric depression scale is a self-report measure of depression in older adults. The minimum score is 0 and the maximum score is 15. Higher scores indicate greater severity of depressive symptoms and lower scores indicate lesser severity of depressive symptoms.

    Time frame: Baseline (week 0), Post-intervention (week 12), Follow-up (week 24)

  4. LifeSpace Assessment

    The LifeSpace Assessment assesses mobility from the spaces that older adults go, and how often, and how independently they move. The minimum score is 0 and the maximum score is 120. Higher scores indicate a larger life space and lower scores indicate a smaller life space.

    Time frame: Baseline (week 0), Post-intervention (week 12), Follow-up (week 24)

  5. PDQ-39

    It is a self-administered questionnaire to assess PD-specific health-related quality of life. The 39-item self-report questionnaire will be used to asses quality of life. The questionnaire has 8 domains (e.g. mobility, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort). It contains questions asking how often certain difficulties/problems have occurred within the last month with answers ranging from "never" to "always." Each dimension total score ranges from 0 (never have difficulty) to 100 (always have difficulty). Higher scores indicate poorer quality of life and lower scores indicate higher quality of life.

    Time frame: Baseline (week 0), Post-intervention (week 12), Follow-up (week 24)

  6. Sensor-based mobility

    Wearable sensor data features will be extracted from the data such as active and sedentary time, gait speed, and others.

    Time frame: Baseline (week 0), Post-intervention (week 12), Follow-up (week 24)

07

Study locations

1 of 1 sites recruiting
  • Rutgers University
    Newark, New Jersey 07107, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Following the completion of this study, the deidentified data set resulting from this body of work will be added to an open source data bank for use by future researchers.

Supporting information: Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05551338
Lead sponsor
Rutgers, The State University of New Jersey
Responsible party
Jean-Francois Daneault, Ph.D. (Assistant professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Sep 22, 2022
Start date
Jun 15, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Sep 22, 2022

Study contacts

Jean-Francois Daneault
Contact
jf.daneault@rutgers.edu
9739728482

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion